Resolutions Voted at the AGM
Oncolytics Biotechâs Annual General Meeting covered the standard governance items that most public companies present to shareholders:
| Resolution | Description | Outcome |
|---|---|---|
| Election of Directors | Reâelection of the existing board members and election of two new directors to fill vacant seats. | All incumbent directors were reâelected and the two new directors were elected with >âŻ99âŻ% of the votes cast in favour. |
| Ratification of the Independent Auditor | Approval of Grant Thornton LLP (or the appointed auditor) for the 2025â2026 audit year. | Ratified â 100âŻ% of the votes supported the auditor. |
| Adoption of the Shareholder Rights Plan (Poison Pill) | Continuation of the existing rightsâplan that caps any single shareholderâs ownership at 10âŻ% without board approval. | Approved â the plan was adopted unanimously. |
| Approval of the Annual Budget & Business Plan | Authorization of the 2025â2026 operating plan, including the planned PhaseâŻIII trial spend for pelareorep. | Accepted â >âŻ98âŻ% of votes in favour. |
| Appointment of Officers | Confirmation of the appointment of the President & CEO and other senior officers. | All appointments were approved with no dissent. |
Trading Implications
The cleanâsweep of all resolutionsâespecially the reaffirmation of the shareholderârights plan and the unopposed reâelection of the boardâsignals strong internal cohesion and a stable governance environment. From a fundamentals perspective, there are no immediate redâflag changes to the capital structure or strategic direction; the company remains on its current immunotherapy development trajectory, with the upcoming PhaseâŻIII trial for pelareorep still the primary catalyst.
Technically, the stock has been trading in a tight range around the $1.20â$1.30 level since the AGM announcement, reflecting the marketâs ânothing newâ view. The absence of dissenting votes removes a potential source of volatility, suggesting the next priceâmove drivers will be trial data releases or broader biotech sector sentiment rather than governanceârelated surprises. For traders, the AGM outcome is a neutralâtoâpositive signal: maintain existing positions, but focus on upcoming clinicalâtrial milestones for upside potential, while keeping a watch on sectorâwide risk on news (e.g., FDA guidance, macroârisk).